IV-361 - ≥98% , CAS No.2055741-39-2

CAS: 2055741-39-2 Cat. No.: I649000 Summenformel: C₂₃H₃₂FN₅O₂Si Molekulargewicht: 457.62

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Übersicht

IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)

In Vitro

IV-361 has less inhibition on CDK2 (K i ≥1000 nM) or PLK1 (K i ≥5000 nM). IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC 50 ≤100 nM) in periphery blood mononuclear cell (PBMC). IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI 50 ≤100 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116 . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:CDK7 ≤50 nM (Ki) CDK2 ≥1000 nM (Ki)

Specifications

Spezifikationen & Reinheit

≥98%

Biochemische und physiologische Mechanismen

IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1).

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

INHIBITOR

Reinheit

≥98%

Namen und Kennungen

• Molekulargewicht: 457.62

Chemische und physikalische Eigenschaften

• Löslichkeit: DMSO : 90 mg/mL (196.67 mM; Need ultrasonic)